iRadimed (NASDAQ:IRMD) Updates FY 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) updated its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 2.090-2.240 for the period, compared to the consensus estimate of 1.960. The company issued revenue guidance of $91.0 million-$96.0 million, compared to the consensus revenue estimate of $91.2 million. iRadimed also updated its Q3 2026 guidance to 0.540-0.590 EPS.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on IRMD. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Weiss Ratings downgraded iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $120.00.

iRadimed Trading Down 4.6%

Shares of IRMD stock traded down $4.35 on Friday, hitting $90.86. 308,080 shares of the stock were exchanged, compared to its average volume of 107,190. The firm’s 50 day moving average is $94.56 and its two-hundred day moving average is $95.73. iRadimed has a one year low of $57.83 and a one year high of $107.90. The firm has a market capitalization of $1.16 billion, a PE ratio of 49.65 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.03. The firm had revenue of $21.98 million during the quarter, compared to the consensus estimate of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. On average, sell-side analysts expect that iRadimed will post 1.52 earnings per share for the current year.

Insider Transactions at iRadimed

In other news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the sale, the chief executive officer directly owned 2,162,500 shares of the company’s stock, valued at approximately $195,922,500. This represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 21,250 shares of company stock worth $1,836,403. Corporate insiders own 34.60% of the company’s stock.

More iRadimed News

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of IRMD. Quarry LP purchased a new stake in iRadimed in the third quarter valued at approximately $40,000. Tower Research Capital LLC TRC raised its position in shares of iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 495 shares in the last quarter. Virtus Advisers LLC bought a new stake in shares of iRadimed during the 3rd quarter worth $117,000. Aquatic Capital Management LLC lifted its holdings in shares of iRadimed by 210,400.0% during the 3rd quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock worth $150,000 after acquiring an additional 2,104 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in iRadimed in the third quarter valued at $164,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.